Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Sidedness as Drivers of Treatment Decisions in CRC

November 21st 2018

Treatment Options for Right-Sided CRC

November 21st 2018

Treatment Options for First- and Second-Line Left-Sided CRC

November 21st 2018

Optimal Therapy for BRAF-Mutated mCRC

November 21st 2018

Application of Molecular Testing Results in Treating mCRC

November 21st 2018

Molecular Testing for Newly Diagnosed mCRC

November 21st 2018

Treating Locally Advanced Rectal Cancer

November 21st 2018

Maintaining Wellness After Treatment

November 21st 2018

Optimal Duration of Therapy for Stage III Colon Cancer

November 21st 2018

Treatment Options for High-Risk Stage II Colon Cancer

November 21st 2018

Efficacy of Adjuvant Therapy in Stage II Colon Cancer

November 21st 2018

Current Role of Adjuvant Therapy for Colon Cancer

November 21st 2018

Dr. Cercek on Chemotherapy Resistance in dMMR Rectal Cancer

November 20th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Dabrafenib Plus Trametinib Demonstrates Activity in GI Cancers

November 17th 2018

The combination of dabrafenib and trametinib led to encouraging responses in patients with rare, incurable cancer of the digestive tract.

Novel Agent Active Across Heavily Pretreated HER2+ Tumors

November 17th 2018

The novel bispecific antibody ZW25 induced a disease control rate of 82% in heavily pretreated patients across several HER2-positive tumor types, according to phase I study results presented at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.

Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC

November 17th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).

Novel Drug Combination Shows Early Activity in Microsatellite Stable CRC

November 17th 2018

Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

Dr. Berk on Immunotherapy Options for Patients With Colon Cancer

November 17th 2018

Seth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.

Future Research and the Clinical Management of mCRC

November 16th 2018

Additional Considerations for Targeted Therapy in mCRC

November 16th 2018